The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
The sales momentum comes as Elanco prepares to open its $200 million-plus corporate campus next month on the west side of downtown Indianapolis.
The recommendation applies to a range of GLP-1 drugs that also includes Novo Nordisk’s Ozempic and Lilly’s older diabetes treatment, Trulicity.
The threat comes as Trump also pressures drugmakers to lower prices of pharmaceuticals in the United States.
Eli Lilly and Co. announced this month it would raise the weight-loss treatment’s price by as much as 170%, presenting pharmacies with a dilemma about how much they would pass on to patients.
The company’s shares rose as much as 4.3% Tuesday after Eli Lilly announced the trial results for orforglipron.
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand for direct sales. Lilly is working with Truepill and Amazon.com Inc.’s pharmacy unit on its platform.
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
Seventeen of the complaints also name Eli Lilly and Co. competitor Novo Nordisk Inc. as a defendant and make similar allegations about its GLP-1 drug, Ozempic.
Attorney General Todd Rokita announced Monday that Indiana is expected to receive another $16.5 million as part of the latest multistate opioid settlement.
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.
The idea could help the administration achieve one of President Donald Trump’s main health-care goals: ensuring foreign countries aren’t getting a better deal on drugs.
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.
The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.
Most of the money would go to state and local governments to address the nation’s addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims.
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.
